-
Application for clinical application of two new drugs of class 1.1 in Kelun pharmaceutical
Time of Update: 2020-04-03
According to the information from the State Food and Drug Administration on April 15, the application of ceftoren sodium phosphate for injection and ceftoren sodium for injection by Kelun Pharmaceutic
-
Baiyunshan 3.1 new drug gefitinib API accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on August 4, the class 3.1 new drug gefitinib API declared by Baiyunshan was accepted At present, only the original research d
-
Application for clinical approval of Tianjin International Biomedical Joint Research Institute and Furen Pharmaceutical Co., Ltd. "special project for anti cancer of p-tetrabenzoamide"
Time of Update: 2020-04-03
The research and development project of "anti-cancer project of p-tetrabenzamide" jointly carried out by Tianjin International Biomedical Joint Research Institute and Furen Pharmaceutical Co., Ltd has
-
Qianhong pharmaceutical's development of new drugs has been frustrated and antithrombotic protein has been withdrawn from trial
Time of Update: 2020-04-03
Today (November 7), the investors of Qianhong pharmaceutical finally waited for the latest news of the company's heavyweight new drug, recombinant human antithrombotic protein for injection (hereinaft
-
Thermodox, a liver cancer drug of celsion, a partner of Haizheng pharmaceutical, has not reached the end of clinical study
Time of Update: 2020-04-03
Haizheng Pharmaceutical Co., Ltd announced on the evening of January 31 that it would terminate its cooperation with the company on the product, because the company's partner, U.S celsion company, ann
-
Huashen group's second application for production of 6.1 rhinitis traditional Chinese medicine Wulong granules was accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on May 9, Wulong granules, a 6.1 rhinitis traditional Chinese medicine, which was applied for production (reexamination) by Hu
-
Triptoreline acetate sustained-release microspheres for green leaf pharmaceutical injection obtained clinical approval
Time of Update: 2020-04-03
LVYE Pharmaceutical Group Co., Ltd announced that triptoreline acetate sustained-release microspheres (ly01007) for injection, the group's product under development, have been approved by China food a
-
Ibalizumab (tmx-355), a McAb for AIDS treatment produced by Wuxi apptec for Zhongyu new drug, was approved by FDA
Time of Update: 2020-04-03
Ibalizumab is a human monoclonal antibody drug developed by Zhongyu new medicine to treat HIV / AIDS infection It is an innovative AIDS therapy called "virus invasion inhibitor" Wuxi biopharmaceutical
-
Shenzhen Institute of advanced technology, Chinese Academy of Sciences: ultrasound administration or reversal of multidrug resistance
Time of Update: 2020-04-03
On December 17, the reporter learned from Shenzhen Institute of advanced technology of Chinese Academy of Sciences that Zheng Hailong's research group of the Institute of medical engineering of Chines
-
The University of Hong Kong has successfully developed a new influenza A vaccine
Time of Update: 2020-04-03
Recently, the University of Hong Kong has successfully developed a new influenza A vaccine The inoculated mice can prevent the infection of a variety of a influenza viruses including h7n9 A avian infl
-
Three new drugs made in Beijing
Time of Update: 2020-04-03
After the Spring Festival, "pirfenidone", a new drug for the treatment of idiopathic pulmonary fibrosis, went on the market The production acceptance of the vaccine for the prevention of HFMD was comp
-
Summary of drug approval documents in April 2014
Time of Update: 2020-04-03
According to the new drug mailing approval information publicly released by the State Food and drug administration, the pharmaceutical group of big smart news agency has sorted out a summary of new dr
-
New anticancer drugs of Fosun Pharmaceutical holding subsidiary obtained clinical approval again
Time of Update: 2020-04-03
Fosun Pharmaceutical announced today that the recombinant anti HER2 humanized monoclonal antibody for injection developed by its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd (accep
-
Delivery information of semidone tablet, a new drug of Xianju pharmaceutical
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on June 4, the delivery information of semidone, a heavy-duty anti pregnancy drug, which was applied for production by Xianju
-
East China medicine class 1 antitumor drug mehuatinib applied for clinical acceptance
Time of Update: 2020-04-03
According to the information on CFDA website, the clinical application of the first class antitumor drug of East China medicine, mehuatinib API and tablet, has been accepted East China medicine is the
-
The first artificial drug of humanwell is expected to go on sale in the second half of the year
Time of Update: 2020-04-03
Li Jie, chairman of Yichang humanwell, a subsidiary of humanwell pharmaceutical, said at the institutional research meeting on March 26 that the company's newly approved narcotic and analgesic drug, n
-
Lansoprazole for injection in Wuzhong, Jiangsu Province will add a new army of drugs for digestive tract
Time of Update: 2020-04-03
According to the information released by the State Food and Drug Administration (CFDA), Lansoprazole for injection, a new class 3 chemical drug in Wuzhong, Jiangsu Province (600200 SH), will undergo o
-
Jichuan pharmaceutical pulifloxacin dispersible tablets will be on the market
Time of Update: 2020-04-03
In February 2014, two new varieties of pulifloxacin dispersible tablets and iron albuminosuccinate oral solution in Jichuan pharmaceutical industry were approved successively, and the marketing progre
-
Zuelacetan, an antiepileptic drug of Jingxin pharmaceutical, has obtained new drug certificate and registration approval
Time of Update: 2020-04-03
Zhejiang Jingxin pharmaceutical announced that the company and its wholly-owned subsidiary Shangyu Jingxin Pharmaceutical Co., Ltd received the new drug certificate (Certificate No.: gdzzh20140034) ap
-
Clinical approval of recombinant human anti TNF α monoclonal antibody for injection
Time of Update: 2020-04-03
Jiankangyuan and Lizhu group's joint-venture subsidiary announced today (March 7) that Zhuhai Lizhu monoclonal antibody Biotechnology Co., Ltd (hereinafter referred to as monoclonal antibody company)
